FASN inhibition as a potential treatment for endocrine-resistant breast cancer.

Saved in:
Bibliographic Details
Title: FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
Authors: Gruslova A; UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA., McClellan B; The University of Texas At Austin, Austin, TX, USA., Balinda HU; UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA., Viswanadhapalli S; Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX, USA., Alers V; UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA., Sareddy GR; Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX, USA., Huang T; UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA., Garcia M; UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA., deGraffenried L; The University of Texas At Austin, Austin, TX, USA., Vadlamudi RK; Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX, USA., Brenner AJ; UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA. brennera@uthscsa.edu.; South Texas Research Facility, University of Texas Health San Antonio, STRF 2.208.58403 Floyd Curl Dr, San Antonio, TX, 78229, USA. brennera@uthscsa.edu.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Jun; Vol. 187 (2), pp. 375-386. Date of Electronic Publication: 2021 Apr 24.
Publication Type: Journal Article
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1573-7217
DOI:10.1007/s10549-021-06231-6